Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mixed Phase III results for AstraZeneca's Zactima in lung cancer

This article was originally published in Scrip

Executive Summary

AstraZeneca's new multi-targeted anticancer Zactima (vandetanib) has succeeded in a Phase III trial testing it as a second-line therapy in advanced non-small cell lung cancer (NSCLC), in prolonging progression-free survival (PFS), but has failed in two others to meet its primary PFS endpoint. The trials were in patients with both non-squamous and squamous NSCLC.

Advertisement

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC032042

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel